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AbstrAct
Epithelial to mesenchymal transition (EMT) of cancer cells involves loss of 
epithelial polarity and adhesiveness, and gain of invasive and migratory mesenchymal 
behaviours. EMT occurs in prostate cancer (PCa) but it is unknown whether this is in 
specific areas of primary tumours. We examined whether any of eleven EMT-related 
proteins have altered expression or subcellular localisation within the extraprostatic 
extension component of locally advanced PCa compared with other localisations, and 
whether similar changes may occur in in vitro organotypic PCa cell cultures and in vivo 
PCa models. Expression profiles of three proteins (E-cadherin, Snail, and α-smooth 
muscle actin) were significantly different in extraprostatic extension PCa compared 
with intra-prostatic tumour, and 18/27 cases had an expression change of at least one 
of these three proteins. Of the three significantly altered EMT proteins in pT3 samples, 
one showed similar significantly altered expression patterns in in vitro organotypic 
culture models, and two in in vivo Pten-/- model samples. These results suggest that 
changes in EMT protein expression can be observed in the extraprostatic extension 
component of locally invasive PCa. The biology of some of these changes in protein 
expression may be studied in certain in vitro and in vivo PCa models.
INtrODUctION
It is estimated that 220,800 men in the United States 
will be diagnosed with prostate cancer (PCa) during 2015 
and 27,540 men will die from this malignancy [1], usually 
from metastatic disease. Within the TNM classification 
of PCa, the pT3a stage of this malignancy describes 
extraprostatic extension of the tumour beyond the prostatic 
capsule. Extraprostatic extension of PCa is associated with 
recurrence and metastasis following radical treatment 
[2-5]. Adjuvant treatment after radical prostatectomy 
(RP) depends on histopathological findings predictive of 
recurrence and survival, such as surgical margin status 
and pathological stage [6-8]. Biomarkers are associated 
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with clinical outcome following RP, but none are routinely 
used in clinical practice as they have not demonstrated 
additional prognostic value and clinical utility beyond 
standard care.
Epithelial to mesenchymal transition (EMT) 
describes loss of epithelial cell polarity and adhesion, 
and gain of migratory invasive mesenchymal behaviours 
[9]. EMT occurs during embryogenesis, and can promote 
adenocarcinoma cell invasiveness and metastasis [10, 11]. 
EMT occurs in several cancers including PCa [12-18] and 
can predict recurrence after RP [19, 20], but it is unknown 
whether it occurs in specific areas of primary PCa such as 
extraprostatic extension in pT3a tumours. We investigated 
potential differences in EMT protein expression between 
the extraprostatic extension and intraprostatic tumour 
components of pT3a PCa in RP specimens. In light of 
the increasing research interest in the process of EMT as 
a mechanism of PCa progression, we also investigated 
whether in vitro and in vivo PCa models commonly used 
in the laboratory to investigate mechanisms of PCa cellular 
invasion such as EMT demonstrate any similar changes to 
those observed in human pT3a RP specimens.
rEsULts
The expression of EMT proteins in whole mount 
sections from 27 cases of pT3a PCa (Table 1) was 
analysed. We observed significantly altered expression 
of three proteins in extraprostatic extension versus 
intraprostatic cancer (increased cytoplasmic α-smooth 
muscle actin, decreased membranous and increased 
cytoplasmic E-cadherin, and decreased membranous 
Snail; adjusted-p < 0.05 for each) (Figure 1). These cases 
demonstrated heterogeneous EMT protein expression, 
with 18/27 (67%) showing “strong” or “moderate” 
expression changes of at least one of these three EMT-
related proteins (Figure 2). The most consistent alteration 
in EMT-related protein expression in these clinical cases 
is seen for membranous E-cadherin, with 11 of the 27 
pT3a cases demonstrating strong decreased expression 
in extraprostatic extension versus intraprostatic tumour. 
No statistically significant association was seen 
between EMT-related protein expression changes in the 
extraprostatic extension versus intraprostatic component 
of pT3a disease and Gleason sum score of the pT3a focus 
of tumour. Next, we looked to see if any of the changes 
in EMT-related protein expression observed in the pT3a 
wholemount sections could be seen in cases from a 
“heterogeneity” tissue microarray comprising samples 
from 13 patients and including tissue cores from the 
extraprostatic extension focus, “mid-portion”, and “deep” 
focus of pT3a PC, a separate pT2 focus, and from various 
histologically benign regions of the prostate (Table 2). A 
trend towards increased cytoplasmic α-smooth muscle 
actin and increased cytoplasmic E-cadherin was observed 
in extraprostatic extension versus pT3a “mid-“ and 
“deep”-areas (Figure 3) in these TMA samples. For several 
EMT-related proteins the pattern of expression in the 
extraprostatic extension component of pT3a disease was 
similar to that observed in a separate focus of pT2 disease 
(Figure 3), despite the fact that the Gleason scores of the 
extraprostatic extension component of the pT3a samples in 
the “heterogeneity” TMA were significantly different from 
those of the separate pT2 foci (Table 2). 
No significant differences in EMT-related protein 
expression in the x27 wholemount pT3a were observed 
between various subclassifications of extraprostatic 
extension [2] (Figure 4). Control experiments 
using the pT3a wholemount samples excluded 
immunohistochemistry (IHC) “edge artefacts” and tissue 
trauma (Figure S1). In order to analyse interobserver 
reproducibility two uropathologists independently 
scored α-smooth muscle actin (αSMA) and E-cadherin 
expression in 10 randomly selected cases of pT3 PCa. 
Moderate agreement was observed between independent 
uropathologists for αSMA (κ score 0.438) and fair 
agreement was observed for E-cadherin (κ score 0.213).
Next, we investigated whether EMT protein 
expression changes observed in extraprostatic extension 
samples might occur in in vitro organotypic cultures 
of invasive PCa cells. A similar expression change of 
membranous E-cadherin was observed in invading PC3 
cells compared with non-invading upper surface cells (p < 
0.05) (Figure 5). We also observed decreased cytoplasmic 
β-catenin (PC3), increased nuclear Gli2 (PC3), increased 
cytoplasmic N-cadherin (PC3), decreased nuclear NFκB 
p65 (LNCaP), increased cytoplasmic NFκB p65 (DU145), 
increased cytoplasmic Twist (PC3) and increased 
cytoplasmic vimentin (PC3 & DU145) expression (p < 
0.05 for each) in the in vitro organotypic culture cell line 
experiments. 
Finally, we investigated whether EMT expression 
changes might occur in an in vivo Pten-/- mouse model of 
invasive PCa. Significant expression changes of α-smooth 
muscle actin, E-cadherin and Snail were observed in 
tumours in Pten-/- mice (n = 7) compared with benign 
Pten+/+ mice (n = 6) (adjusted-p < 0.05) (Figure 6).
DIscUssION
These results suggest EMT occurs in extraprostatic 
extension components of locally advanced PCa. The 
mechanisms driving PCa cell metastasis are unclear, and 
it is unknown whether metastatic clones originate within 
the extraprostatic extension component or from clones 
within intraprostatic tumour, although a recent study 
suggests the latter is possible [21]. Several models of PCa 
cellular invasiveness exist [22], including cohesive groups 
of cells budding away from precursor lesions [23], and 
single cancer cells undergoing EMT and invading stroma 
and vasculature [24, 25]. Our study builds on existing 
evidence [18] by demonstrating that EMT occurs in PCa, 
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Figure 1: Analysis of EMt-related protein expression changes in locally advanced invasive prostate cancer. The 
expression profiles of eleven candidate EMT-related proteins were analysed in extraprostatic and intraprostatic regions of 27 cases of 
locally advanced invasive prostate cancer in radical prostatectomy specimens. Significantly increased cytoplasmic α-smooth muscle actin, 
increased cytoplasmic E-cadherin, decreased membranous E-cadherin, and decreased membranous Snail expression (*adjusted-p < 0.05 
for each) was observed in extraprostatic foci of prostate cancer compared with intraprostatic tumour. 
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table 1: Demographics and baseline radical prostatectomy pt3a prostate cancer characteristics
pt3a prostate cancer 
(n = 27)
Median age (range) 63 (48-73) years
Preoperative PSA
≤10 21
10.1-20 4
>20 2
pN-stage
pNX
pN0
9
17
≥pN1 1
Gleason grade
≤6 0
7 (3+4) 15
7 (4+3) 9
≥8 3
table 2: Analysis of Gleason grades of separate prostate cancer foci 
within a “heterogeneity” prostate cancer tissue microarray
The “heterogeneity” tissue microarray comprises samples from 13 patients and includes tissue cores from the extraprostatic 
extension focus, “mid-portion”, and “deep” focus of pT3a prostate cancer, a separate pT2 focus, and from various histologically 
benign regions of the prostate. The Gleason scores of the extraprostatic extension component of the pT3a samples in the 
“heterogeneity” tissue microarray were significantly different from those of the separate pT2 foci.
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Figure 2: Investigating potential associations between the degree of changes in expression of EMt-related proteins at 
the extraprostatic component of pt3a prostate cancer, and prostate cancer Gleason grade. The 27 cases of pT3a prostate 
cancer demonstrated variability with regards to their changes in expression of EMT-related proteins (colour key: ≤ -100 strongly, -99 to 
-70 moderately, and -69 to -40 mildly decreased expression; -39 to +39 no altered expression; +40 to +69 mildly, +70 to +99 moderately, 
and ≥ +100 strongly increased expression). These cases demonstrated heterogeneous EMT protein expression, with 18/27 (67%) showing 
moderate or strong expression changes of at least one of these three EMT-related proteins. No significant relationship was observed 
between the number of EMT-related proteins altered in the extraprostatic versus intraprostatic component of these pT3a tumours and the 
Gleason sum score (p > 0.05) or primary Gleason grade pattern (p > 0.05).
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and when observed in other cancers EMT contributes to 
metastasis [26]. EMT in cancer invasion is not universally 
observed [27-30], and distinguishing cancer cells with a 
mesenchymal phenotype from stromal cells or fibroblasts 
can be difficult. Our results suggest changes in EMT-
related protein expression in the extraprostatic extension 
component of PCa is not an “all or nothing” phenomenon, 
and co-expression of mesenchymal markers in EMT in 
PCa is reportedly uncommon [18].
PCa is often multi-focal with intra-tumoral genomic 
heterogeneity, and EMT may be heterogeneous. Several 
of the protein expression changes we observed in 
extraprostatic extension have been reported elsewhere, 
including PCa, such as reduced membranous [12] and 
increased cytoplasmic E-cadherin [31-34], and increased 
cytoplasmic α-smooth muscle actin [35]. Snail is a 
transcription factor overexpressed during PCa EMT [36], 
therefore the reduced membranous Snail observed in 
extraprostatic extension in our study, and the increased 
cytoplasmic Snail seen in the Pten-/- mouse model, along 
with the difference in subcellular localisation of Snail 
between human, cell line and mouse samples, is difficult to 
explain, but may represent altered subcellular localisation 
of a multi-functional protein in these different sample 
types. Our observation that vimentin was expressed in 
some benign prostate epithelial cells, but not within cancer 
cells, is intriguing as vimentin is reportedly overexpressed 
in invasive PCa cells undergoing EMT [37]. However, 
vimentin expression has been observed in benign 
prostate epithelium cases with concomitant PCa [18, 
38]. Heterogeneous expression of vimentin in different 
intraprostatic locations might account for these differences 
in subcellular localisation. Whilst studies have shown that 
EMT correlates with adverse features in malignancies 
including PCa [39-47], we did not observe significant 
associations between the degree of protein expression 
change and Gleason score, possibly due to sample size.
The observations in “heterogeneity” TMA 
experiments suggesting that, for at least some of the 
EMT-related protein expression changes, the separate 
pT2 focus of tumour looked similar to the pT3a 
extraprostatic extension component, were intriguing. 
These results cannot be easily explained, and were not 
due to differences in the relative Gleason sum scores of 
these separate tumour foci. It is an intriguing possibility 
that metastases may arise from seeding foci within areas 
of pT2 PCa, rather than from PCa cell clones within the 
extraprostatic extension region of pT3a foci, and this 
warrants further investigation. Indeed, it is evident that 
metastatic clones of cells may arise from intraductal PCa 
[21]. Moreover, EMT-related changes are not an “all or 
nothing” phenomenon, therefore some of these changes 
may be seen in separate pT3a and pT2 tumour foci in 
multi-focal PCa. This requires further investigation.
The observation that several EMT-related proteins 
with differential expression in extraprostatic versus 
intraprostatic cancer were similarly altered in a Pten-
/- in vivo model of PCa suggests these changes may be 
Figure 3: similar changes in EMt-related protein expression to those observed in whole-mount specimens can be 
observed within discrete foci of abnormality within a “heterogeneity tissue microarray”. This microarray contains 7 cores 
(one from each of the extraprostatic extension component, central tumour, and “deep” tumour of the “index” prostate cancer, one from a 
synchronous focus of pT2 prostate cancer, one from each of the adjacent and distant benign peripheral zone, and one from the transitional 
zone) from each of 13 radical prostatectomy cases. A trend towards increased cytoplasmic α-smooth muscle actin and increased cytoplasmic 
E-cadherin was observed in extraprostatic extension versus pT3a “mid-“ and “deep”-areas in these samples. For several EMT-related 
proteins the pattern of expression in the extraprostatic extension component of pT3a disease was similar to that observed in a separate focus 
of pT2 disease.
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biologically relevant in these tumours. Significant changes 
in expression of EMT proteins were seen in the PCa 
cells (PC3 and DU145) in in vitro organotypic cultures 
demonstrating “collective cell invasion” [48]. The fact 
that only PC3 cells demonstrated any similar changes to 
the observations in RP tumours suggests that some aspects 
of human PCa cell biology cannot be fully recapitulated 
by in vitro cell line experiments. Selection of cell lines 
for particular experiments will depend on aspects of cell 
biology under investigation. 
A limitation of our study is the sole focus on IHC 
changes in EMT-related proteins within extraprostatic 
extension versus intraprostatic tumour, which are 
recognized to be potentially variable. Whilst IHC is 
the commonest current tool in diagnostic pathology, it 
is important for future studies to investigate potential 
changes in PCa biology at the extraprostatic extension foci 
of pT3a tumours using molecular biology techniques such 
as sequencing. It would be beneficial for future studies 
to validate the sub-cellular location of these EMT-related 
proteins using sub-cellular samples extracted from freshly 
acquired tissues.
A further limitation of this study is the difficulty 
assessing distinct areas of extraprostatic extension in 
Pten-/- in vivo mouse models of invasive PCa, and then 
comparing this with intraprostatic tumour, as the mouse 
prostate lacks a discrete capsule [49]. Nevertheless, we 
observed significantly increased cytoplasmic aSMA and 
E-cadherin expression in both extraprostatic extension 
locally invasive advanced human PCa samples and 
malignant cells within the in vivo mouse model, suggesting 
that it might be worthwhile investigating the significance 
of changes in subcellular localization of these EMT-related 
proteins in further studies.
It will be important to determine whether pT3a PCa 
with extraprostatic extension EMT has different outcomes 
following radical surgery compared with matched 
tumours without EMT. This may influence decision-
making regarding post-operative salvage radiotherapy. A 
larger study with longer clinical follow-up is required to 
investigate this. Experiments to identify potential clinical 
utility of analysis of EMT-related protein expression in 
prostate biopsies are warranted.
In summary our results suggest that changes 
in expression of EMT-related proteins occur in the 
extraprostatic extension component of locally invasive 
PCa, and these changes can be observed in in vitro and 
in vivo PCa models commonly used in the laboratory to 
studies mechanisms of PCa cellular invasion.
Figure 4: the expression of EMt-related proteins was unrelated to the degree of prostate cancer extraprostatic 
extension. Extraprostatic extension can be classified as focal and non-focal, or ≤1mm and >1mm [2]. No significant difference in the 
expression of EMT-related proteins was seen between either type of extraprostatic extension classification.
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Figure 5: Analysis of EMt-related protein expression in an in vivo organotypic culture model of cellular invasiveness. 
Of the four changes in EMT-related protein expression seen in human pT3 samples, decreased membranous E-cadherin expression was also 
observed in invasive PC3 prostate cancer cells in an in vitro organotypic culture model of cellular invasiveness (p < 0.05). Several other 
significant changes in EMT-related protein expression were seen in PC3, DU145 and LNCaP cells in this in vitro organotypic cell culture 
model. N - nuclear, C - cytoplasmic, M - membranous.
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Figure 6: Analysis of EMt-related protein expression in a Pten-/- in vivo model of invasive prostate cancer. The expression 
profiles of the three significantly altered EMT-related proteins in human pT3 prostate cancers were studied in an in vivo Pten-/- model of 
invasive prostate cancer. Two of the EMT-related proteins that were altered in human samples (increased cytoplasmic alpha smooth muscle 
actin and E-cadherin) showed similar changes in expression in prostate cancer cells in the Pten-/- model compared with benign prostate 
epithelial cells in Pten+/+ mice (adjusted-p < 0.05). 
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MAtErIALs AND MEtHODs
radical prostatectomy specimens
Whole mount sections from formalin-fixed paraffin-
embedded pT3a PCa samples from 27 patients treated 
with RP were reviewed by a uropathologist to identify 
extraprostatic extension on diagnostic H&E sections. 4μm 
sections were cut from mega paraffin blocks containing 
4mm transverse slices of prostate tissue. The area with 
extraprostatic extension was selected on the water bath 
after cutting to ensure that it was included on each whole 
mount section. This study had appropriate ethical approval 
(ProMPT ethics reference number MREC 01/4/61, P.I. 
Professor FC Hamdy).
tissue microarray specimens
The “heterogeneity” TMA contains 7 cores 
(one from each of the extraprostatic extension, central 
tumour, and “deep” tumour of the index PCa, one from 
a synchronous focus of pT2 PCa, one from each of the 
adjacent and distant benign peripheral zone, and one 
from the transitional zone) from each of 13 RP cases. The 
construction of the “heterogeneity” TMA had appropriate 
ethical approval (Oxford Radcliffe Biobank ethics 
reference number 09 H0606 5+5).
Organotypic cultures
Organotypic cultures of PC3, DU145 and LNCaP 
cells were generated as described previously [50-53].
Pten-/- mouse prostate cancer samples
Prostate samples from each prostate lobe (ventral, 
anterior and dorsolateral) from 6 Pten+/+, and from each 
invasive PCa from 7 Pten-/- mice, were analysed.
Antibodies
Primary antibodies (Abcam, UK, and 1:50 dilution 
unless otherwise stated) used for IHC included rabbit 
anti-α smooth muscle actin (ab5694, 1:200), mouse anti-
β-catenin (M3539, DAKO Ltd, UK, 1:100), rabbit anti-
E-cadherin (ab53033, 1:1500), rabbit anti-Fibronectin 
(ab2413, 1:150), rabbit anti-Gli2 (ab26056), rabbit anti-N-
cadherin (ab12221, 1:400), rabbit anti-NFκB p65 (ab7970, 
1:1000), rabbit anti-Sonic Hedgehog (ab53281), goat 
anti-Snail (AF3639, R&D Systems, USA), rabbit anti-
Twist (ab49254, 1:100), mouse anti-Vimentin (clone V9, 
M0725, DAKO Ltd, UK, 1:100). Secondary antibodies 
used included goat biotinylated anti-mouse IgG (BA-9200, 
Vector Laboratories, USA, 1:250), goat biotinylated anti-
rabbit IgG (BA-1000, Vector Laboratories, USA, 1:250), 
and ImmPRESS peroxidase reagent kit (antigoat MP-7405 
and anti-rabbit MP-7401, Vector Laboratories, USA).
Immunohistochemistry and 
immunocytochemistry
IHC was performed as previously described [50] 
with boiling sodium citrate buffer pH 6 antigen retrieval 
for α-smooth muscle actin, β-Catenin, E-cadherin, 
Fibronectin, Gli2, N-cadherin, NFκB p65, Sonic 
Hedgehog, Twist and Vimentin. All immunohistochemistry 
experiments included negative controls by omitting the 
primary antibody.
semi-quantitative protein expression analysis
Nuclear, cytoplasmic and membranous localisation 
of each EMT-related protein in luminal prostate epithelial 
cells in extraprostatic extension and intraprostatic (defined 
as the “deepest” area of the same tumour away from the 
capsule) PCa, and histologically benign epithelium, in a x4 
field of whole mount RP specimens and in “heterogeneity” 
TMA sections was quantified by a uropathologist. For each 
protein an intensity (0-3) and cell percentage was assigned 
for nuclear, cytoplasmic and membranous expression in 
PCa cells, and these were multiplied to give an expression 
score (range 0-300) for each subcellular compartment. 
Features of extraprostatic extension including focality, 
radial distance and location were noted. The expression of 
each protein was similarly quantified for PCa cells situated 
within the invasive margin or non-invasive upper layer 
of in vitro organotypic cultures, and within the invasive 
margin and central tumour in in vivo Pten-/- mouse PCa.
“Control” analyses were performed for RP 
experiments to exclude histological artefacts. To exclude 
differential fixation in the peripheral and central prostate 
regions, and to exclude “edge artefact’’ (where the section 
edge lifts creating darker staining), SHH and E-cadherin 
expression was quantified at both the extraprostatic 
extension component of pT3a PCa and the innermost “cut 
edge” of the tumour sample in a random whole mount 
section, and the paired samples were compared.
We undertook an analysis of interobserver 
reproducibility using 10 randomly selected cases from 
the samples stained with anti-αSMA and E-cadherin 
antibodies. Reproducibility of protein expression scoring 
for the re-reviewed cases was assessed using κ statistics. 
By convention, a κ score <0 is poor interobserver 
agreement, 0.0-0.20 slight agreement, 0.21-0.40 fair 
agreement, 0.41-0.60 moderate agreement, 0.61-0.8 
substantial agreement and >0.80 almost perfect agreement 
[54].
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statistical analysis
Human pT3 (n = 27) extraprostatic and intraprostatic 
EMT-related protein expression was compared using a 
linear regression model with log-transformed expression 
scores as the response and extra-/intra-prostatic as an 
explanatory variable. This was performed separately for 
each EMT-related protein and for each of the three cellular 
compartments (nuclear, cytoplasmic and membranous). 
p values were adjusted for multiple testing using the 
Benjamini-Hochberg procedure and additionally they were 
compared to their expected values.
EMT-related protein expression in Pten-/- mice (n 
= 7) was compared with expression in each of the three 
lobes (dorsolateral, anterior and ventral) containing benign 
prostate epithelium in wild-type Pten+/+ mice (n = 6) using 
a linear regression model with log-transformed expression 
scores as the response. This was performed separately for 
each EMT-related protein and for each of the three cellular 
compartments (nuclear, cytoplasmic and membranous), 
adjusting for multiple testing as for human pT3 samples 
above.
EMT-related protein expression in cell lines was 
analysed by paired t-tests comparing log-transformed 
values for the innermost layer (invading) and outermost 
layer (non-invading) of cells for each cell line and 
each cellular compartment (nuclear, cytoplasmic and 
membranous). The results were not adjusted for multiple 
testing because n = 3 for each cell line and each cellular 
compartment.
To assess any potential relationship between the 
presence of an EMT-related protein expression difference 
between extraprostatic and intraprostatic human PCa, and 
primary Gleason pattern being ≥4, logistic regression was 
used with the difference in extraprostatic and intraprostatic 
protein expression as an explanatory variable, both with 
and without adjustment for intraprostatic expression. The 
effect of the difference between the extraprostatic and 
intraprostatic component on recurrence was also examined 
using logistic regression.
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